SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Jubilant Ingrevia receives EIR from USFDA for Unit-1 at Bharuch

This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative

Lonza to buy US biologics site from Roche for US$ 1.2 billion

Lonza plans to invest approximately CHF 500 million to upgrade the facility

Solara Active Pharma elevates Arun Kumar Baskaran to the post of CFO

Arun is currently working as Vice President (Strategy) in Solara leading Business finance & Strategy function

Marksans Q3 FY24 revenue up 22% at Rs 586 Cr

Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%

Jubilant Pharmova Singapore to sell its entire 25.8% stake in Sofie Biosciences, USA

JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million

Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr

Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023

Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr

Sales in the US region grew well, partially offset by the decline in the LATAM and European regions

Indian pharma industry to witness 8-10% revenue growth in fiscal 2024: CRISIL

Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable